A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Widgerow A.
Wang J, et al.
J Drugs Dermatol. 2023 Apr 1;22(4):333-338. doi: 10.36849/JDD.7340.
J Drugs Dermatol. 2023.
PMID: 37026875
Clinical Trial.
CONCLUSION: A novel topical product with PATH-3 Technology, designed to counteract various steps in pigmentation pathways, has been demonstrated to be safe and effective in treating facial dyschromia. CITATION: Wang JV, Fabi SG, Mraz Robinson D, et al. A multi-cente …
CONCLUSION: A novel topical product with PATH-3 Technology, designed to counteract various steps in pigmentation pathways, has been demonstr …